尼罗替尼可克服对伊马替尼一线治疗继发耐药的慢性髓性白血病患者的达沙替尼耐药性。 - Suppr | 超能文献

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.

作者信息

Breccia Massimo, Cannella Laura, Nanni Mauro, Stefanizzi Caterina, Alimena Giuliana

机构信息

Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.

出版信息

Acta Haematol. 2007;118(3):162-4. doi: 10.1159/000108639. Epub 2007 Sep 20.

DOI:10.1159/000108639

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.尼罗替尼可克服对伊马替尼一线治疗继发耐药的慢性髓性白血病患者的达沙替尼耐药性。

Acta Haematol. 2007;118(3):162-4. doi: 10.1159/000108639. Epub 2007 Sep 20.

2

Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.作为一名对伊马替尼耐药的慢性髓性白血病患者对达沙替尼耐药机制的费城染色体等臂双体重复。

Leuk Lymphoma. 2011 Jul;52(7):1372-5. doi: 10.3109/10428194.2011.565394. Epub 2011 Apr 4.

3

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.韩国慢性髓性白血病患者在接受 Abl 酪氨酸激酶抑制剂治疗期间 T315I BCR-ABL 激酶结构域突变的动态变化。

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

4

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.

5

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.达沙替尼用于治疗伊马替尼治疗失败后的费城染色体阳性慢性髓性白血病。

Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. doi: 10.1517/14656566.8.18.3257.

6

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.慢性髓性白血病对达沙替尼、尼洛替尼和高剂量伊马替尼反应的动力学

Haematologica. 2014 Nov;99(11):1701-9. doi: 10.3324/haematol.2013.085977. Epub 2014 Sep 12.

7

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.在伊马替尼治疗失败后接受二线达沙替尼或尼洛替尼治疗的慢性髓性白血病患者中，对检测BCR-ABL激酶结构域突变的不同方法进行的合作评估。

Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16.

8

NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.英国国家卫生与临床优化研究所（NICE）针对对伊马替尼耐药或不耐受的慢性粒细胞白血病（CML）患者使用达沙替尼、高剂量伊马替尼和尼罗替尼的指南。

Lancet Oncol. 2012 Feb;13(2):127-8. doi: 10.1016/s1470-2045(12)70008-6.

9

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.已经携带对伊马替尼耐药的Bcr-Abl激酶结构域突变的费城染色体阳性患者，发生与对二线或三线酪氨酸激酶抑制剂耐药相关的其他突变的可能性更高。

Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.

10

Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.达沙替尼通过不同的耐药机制克服了伊马替尼和尼罗替尼在费城染色体阳性慢性髓性白血病中的治疗失败。

Leuk Lymphoma. 2009 May;50(5):848-50. doi: 10.1080/10428190902829425.

引用本文的文献

1

Computational Design of Novel Allosteric Inhibitors for DegP.DegP 的新型别构抑制剂的计算设计。

Molecules. 2021 May 7;26(9):2742. doi: 10.3390/molecules26092742.

2

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.尼洛替尼在慢性髓性白血病一线治疗中的疗效评价。

Cancer Manag Res. 2011 Mar 10;3:65-78. doi: 10.2147/CMR.S11948.